Fiche centre
Irvine Clinical Research
Irvine — United States
Essais liés11clinical trials
VilleIrvinelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07843459
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| Donanemab | Alzheimer | Phase 3 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | RECRUITING |
| Retatrutide | Maladie rénale chronique | Phase 3 | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | ACTIVE_NOT_RECRUITING |
| LY4560736 | Alzheimer | Phase 1 | NCT07843459 | A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) | NOT_YET_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787169 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787182 | A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease | RECRUITING |
| JNJ-64042056 | Alzheimer | Phase 2 | NCT06544616 | Reτain — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| LY3439539 | Alzheimer | Phase 1 | NCT07598370 | A Study of LY3439539 in Participants With Alzheimer's Disease | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |